endometrial cancer

News

MSD's Sac-TMT delivers in first phase 3 readout

MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.

News

Data backs GSK's ovarian cancer blockbuster hopes

GSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.

News

Bayer aims Mirena at women's health issue with no treatment

Bayer has started a phase 3 trial of its Mirena contraceptive in an endometrial disorder, with no treatments, that can lead to cancer.

News

AZ gets landmark approval for Imfinzi/Lynparza combo

AstraZeneca has become the first company to get approval for the combination of an immunotherapy with a PARP inhibitor for treating endometrial cancer.

News

GSK bags sought-after Jemperli okay in endometrial cancer

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions f

News

OS data set up wider Jemperli use in endometrial cancer

GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in th

MSD's Sac-TMT delivers in first phase 3 readout

Data backs GSK's ovarian cancer blockbuster hopes

Bayer aims Mirena at women's health issue with no treatment

AZ gets landmark approval for Imfinzi/Lynparza combo

GSK bags sought-after Jemperli okay in endometrial cancer

OS data set up wider Jemperli use in endometrial cancer

Doctors dismayed by report of NHS AI proposal

Discover a new era of healthcare panel engagement: Grounded ...

endometrial cancer

Editor's Picks